In the context of the cancer immunity cycle and data collected from this Phase 1 study, cavrotolimod has promising PD characteristics for use in combination with CPIs in the first line setting or in patients with disease resistant to PD-1/PD-L1 blockade. Here, PDCD1 is linked to cancer.